下一代糖尿病治療和藥物輸送的全球市場-機會分析/行業預測(2020-2030 年):產品/人口統計(成人/兒童)/適應症/最終用戶
市場調查報告書
商品編碼
1090903

下一代糖尿病治療和藥物輸送的全球市場-機會分析/行業預測(2020-2030 年):產品/人口統計(成人/兒童)/適應症/最終用戶

Next Generation Diabetes Therapy and Drug Delivery Market By Product, By Demographic (Adult Population, Child Population ), By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2020-2030

出版日期: | 出版商: Allied Market Research | 英文 254 Pages | 商品交期: 2-3個工作天內

價格

全球下一代糖尿病治療和藥物輸送市場在預測期內將以 14.28% 的複合年增長率增長,從 2020 年的 70.806 億美元增長到 2030 年預計將增長至 280.4423 億美元。

相對於傳統產品的優勢和增加的醫療成本等因素正在推動這個市場的增長。全球糖尿病患病率的上升和糖尿病患者可支配收入的增加也進一步推動了市場的增長。另一方面,新興市場的低認可度和成本限制預計將成為預測期內抑制市場增長的因素。

本報告調查了下一代糖尿病治療和藥物輸送的全球市場,定義和概述了市場,分析了對市場增長的各種影響因素、市場規模的變化/預測以及各種類別/地區/地區。按主要國家、競爭環境、主要公司概況等分類。

目錄

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義/範圍
  • 主要調查結果
  • 波特五力分析
  • 各大公司的定位
  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • COVID-19:影響分析

第 4 章下一代糖尿病治療和藥物輸送市場:按產品分類

  • 概覽
  • 吸入胰島素
  • 口服胰島素
  • 胰島素貼片
  • CGM 系統
  • 人工胰腺
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按地區
    • 市場分析:按國家/地區

第 5 章下一代糖尿病治療和藥物輸送市場:按生命統計數據

  • 概覽
  • 成人(14歲以上)
  • 兒童(14 歲以下)
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按地區
    • 市場分析:按國家/地區

第 6 章下一代糖尿病治療和給藥市場:按適應症

  • 概覽
  • 1型糖尿病
  • 2型糖尿病
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按地區
    • 市場分析:按國家/地區

第 7 章下一代糖尿病治療和藥物輸送市場:按最終用戶分類

  • 概覽
  • 診斷/臨床
  • 重症監護室
  • 家庭醫療
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按地區
    • 市場分析:按國家/地區

第 8 章下一代糖尿病治療和給藥市場:按地區劃分

  • 概覽
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲/中東/非洲

第 9 章公司情況

  • 主要成功策略
  • 10大公司產品圖
  • 競爭性儀表板
  • 競爭熱圖
  • 主要發展

第 10 章公司簡介

  • Abbott laboratories
  • Dexcom, Inc
  • Eli Lilly and Company
  • Glysens Incorporated
  • Johnson & Johnson
  • MannKind Corporation
  • Medtronic plc
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Senseonics Holdings, Inc.
Product Code: A01768

The global next generation diabetes therapy and drug delivery market was valued at $7,080.6 million in 2020 and is projected to reach $28,044.23 million by 2030, registering a CAGR of 14.28% from 2021 to 2030. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. These products help in the management of the blood glucose level of diabetic patient in minimally invasive manner. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients. It is a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improve management of blood sugar level and reduces the risk of any diabetic-related complications.

The main factors that drive the growth of the next generation diabetes therapy and the drug delivery market include, the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure.

In addition, rise in incidences of diabetes globally and increase in the disposable income among the diabetic patients, further supplement the global next generation diabetes therapy and drug delivery market growth.

Conversely lack of awareness, cost restrains in the developing regions, and less variability in products are expected to obstruct the growth of the market during forecast years. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period.

The global next generation diabetes therapy and drug delivery market is segmented based on product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographics, it is bifurcated into adult population (>14 years) and child population (≤14 years). By indication, it is divided into type 1 diabetes and type 2 diabetes. On the basis of end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key market players profiled in the report include: Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation diabetes therapy and drug delivery market analysis from 2020 to 2030 to identify the prevailing next generation diabetes therapy and drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the next generation diabetes therapy and drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global next generation diabetes therapy and drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patches
  • CGM Systems
  • Artificial Pancreas

By Demographic

  • Adult Population (and14years)
  • Child Population (14years)

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes

By End User

  • Diagnostic/Clinics
  • ICUs
  • Home Healthcare

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbott laboratories
    • Dexcom, Inc
    • Eli Lilly and Company
    • Glysens Incorporated
    • Johnson & Johnson
    • MannKind Corporation
    • Medtronic plc
    • Novo Nordisk A/S
    • Sanofi S.A.
    • Senseonics Holdings, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Inhalable Insulin
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oral Insulin
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Insulin Patches
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 CGM Systems
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country
  • 4.6 Artificial Pancreas
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market analysis by country

CHAPTER 5: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Adult Population (>14years)
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Child Population (14years)
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Type 1 Diabetes
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Type 2 Diabetes
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country

CHAPTER 7: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Diagnostic/Clinics
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 ICUs
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country
  • 7.4 Home Healthcare
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market analysis by country

CHAPTER 8: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Product
    • 8.2.3 North America Market size and forecast, by Demographic
    • 8.2.4 North America Market size and forecast, by Indication
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Product
      • 8.2.6.1.2 Market size and forecast, by Demographic
      • 8.2.6.1.3 Market size and forecast, by Indication
      • 8.2.6.1.4 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Product
      • 8.2.6.2.2 Market size and forecast, by Demographic
      • 8.2.6.2.3 Market size and forecast, by Indication
      • 8.2.6.2.4 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Product
      • 8.2.6.3.2 Market size and forecast, by Demographic
      • 8.2.6.3.3 Market size and forecast, by Indication
      • 8.2.6.3.4 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Product
    • 8.3.3 Europe Market size and forecast, by Demographic
    • 8.3.4 Europe Market size and forecast, by Indication
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Product
      • 8.3.6.1.2 Market size and forecast, by Demographic
      • 8.3.6.1.3 Market size and forecast, by Indication
      • 8.3.6.1.4 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by Product
      • 8.3.6.2.2 Market size and forecast, by Demographic
      • 8.3.6.2.3 Market size and forecast, by Indication
      • 8.3.6.2.4 Market size and forecast, by End User
      • 8.3.6.3 U.K.
      • 8.3.6.3.1 Market size and forecast, by Product
      • 8.3.6.3.2 Market size and forecast, by Demographic
      • 8.3.6.3.3 Market size and forecast, by Indication
      • 8.3.6.3.4 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by Product
      • 8.3.6.4.2 Market size and forecast, by Demographic
      • 8.3.6.4.3 Market size and forecast, by Indication
      • 8.3.6.4.4 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by Product
      • 8.3.6.5.2 Market size and forecast, by Demographic
      • 8.3.6.5.3 Market size and forecast, by Indication
      • 8.3.6.5.4 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Product
      • 8.3.6.6.2 Market size and forecast, by Demographic
      • 8.3.6.6.3 Market size and forecast, by Indication
      • 8.3.6.6.4 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Product
    • 8.4.3 Asia-Pacific Market size and forecast, by Demographic
    • 8.4.4 Asia-Pacific Market size and forecast, by Indication
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 China
      • 8.4.6.1.1 Market size and forecast, by Product
      • 8.4.6.1.2 Market size and forecast, by Demographic
      • 8.4.6.1.3 Market size and forecast, by Indication
      • 8.4.6.1.4 Market size and forecast, by End User
      • 8.4.6.2 Japan
      • 8.4.6.2.1 Market size and forecast, by Product
      • 8.4.6.2.2 Market size and forecast, by Demographic
      • 8.4.6.2.3 Market size and forecast, by Indication
      • 8.4.6.2.4 Market size and forecast, by End User
      • 8.4.6.3 India
      • 8.4.6.3.1 Market size and forecast, by Product
      • 8.4.6.3.2 Market size and forecast, by Demographic
      • 8.4.6.3.3 Market size and forecast, by Indication
      • 8.4.6.3.4 Market size and forecast, by End User
      • 8.4.6.4 Australia
      • 8.4.6.4.1 Market size and forecast, by Product
      • 8.4.6.4.2 Market size and forecast, by Demographic
      • 8.4.6.4.3 Market size and forecast, by Indication
      • 8.4.6.4.4 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by Product
      • 8.4.6.5.2 Market size and forecast, by Demographic
      • 8.4.6.5.3 Market size and forecast, by Indication
      • 8.4.6.5.4 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Market size and forecast, by Product
      • 8.4.6.6.2 Market size and forecast, by Demographic
      • 8.4.6.6.3 Market size and forecast, by Indication
      • 8.4.6.6.4 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Product
    • 8.5.3 LAMEA Market size and forecast, by Demographic
    • 8.5.4 LAMEA Market size and forecast, by Indication
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Product
      • 8.5.6.1.2 Market size and forecast, by Demographic
      • 8.5.6.1.3 Market size and forecast, by Indication
      • 8.5.6.1.4 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Product
      • 8.5.6.2.2 Market size and forecast, by Demographic
      • 8.5.6.2.3 Market size and forecast, by Indication
      • 8.5.6.2.4 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by Product
      • 8.5.6.3.2 Market size and forecast, by Demographic
      • 8.5.6.3.3 Market size and forecast, by Indication
      • 8.5.6.3.4 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by Product
      • 8.5.6.4.2 Market size and forecast, by Demographic
      • 8.5.6.4.3 Market size and forecast, by Indication
      • 8.5.6.4.4 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 Abbott laboratories
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Dexcom, Inc
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Eli Lilly and Company
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Glysens Incorporated
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Johnson & Johnson
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 MannKind Corporation
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Medtronic plc
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Novo Nordisk A/S
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 Sanofi S.A.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 Senseonics Holdings, Inc.
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 2. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INHALABLE INSULIN, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INHALABLE INSULIN BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ORAL INSULIN, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ORAL INSULIN BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INSULIN PATCHES, BY REGION , 2020-2030,($MILLION)
  • TABLE 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INSULIN PATCHES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CGM SYSTEMS, BY REGION , 2020-2030,($MILLION)
  • TABLE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CGM SYSTEMS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ARTIFICIAL PANCREAS, BY REGION , 2020-2030,($MILLION)
  • TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ARTIFICIAL PANCREAS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
  • TABLE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ADULT POPULATION (>14YEARS), BY REGION , 2020-2030,($MILLION)
  • TABLE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ADULT POPULATION (>14YEARS) BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 15. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CHILD POPULATION (14YEARS), BY REGION , 2020-2030,($MILLION)
  • TABLE 16. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CHILD POPULATION (14YEARS) BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
  • TABLE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 1 DIABETES, BY REGION , 2020-2030,($MILLION)
  • TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 1 DIABETES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 20. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 2 DIABETES, BY REGION , 2020-2030,($MILLION)
  • TABLE 21. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 2 DIABETES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 23. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR DIAGNOSTIC/CLINICS, BY REGION , 2020-2030,($MILLION)
  • TABLE 24. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET DIAGNOSTIC/CLINICS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 25. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ICUS, BY REGION , 2020-2030,($MILLION)
  • TABLE 26. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ICUS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 27. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR HOME HEALTHCARE, BY REGION , 2020-2030,($MILLION)
  • TABLE 28. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET HOME HEALTHCARE BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 29. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 30. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 31. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
  • TABLE 32. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
  • TABLE 33. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 34. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 35. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 36. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 37. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 38. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 39. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 40. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 41. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 42. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 43. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 44. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 45. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 46. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 47. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 48. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
  • TABLE 49. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
  • TABLE 50. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 51. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 52. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 53. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 54. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 55. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 56. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 57. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 58. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 59. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 60. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 61. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 62. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 63. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 64. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 65. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 66. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 67. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 68. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 69. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 70. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 71. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 72. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 73. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 74. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 75. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 76. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 77. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
  • TABLE 78. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
  • TABLE 79. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 80. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 81. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 82. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 83. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 84. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 85. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 86. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 87. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 88. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 89. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 90. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 91. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 92. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 93. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 94. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 95. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 96. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 97. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 98. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 99. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 100. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 101. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 102. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 103. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 104. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 105. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 106. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
  • TABLE 107. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
  • TABLE 108. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 109. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 110. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 111. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 112. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 113. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 114. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 115. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 116. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 117. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 118. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 119. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 120. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 121. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 122. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 123. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
  • TABLE 124. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
  • TABLE 125. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 126.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 127.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 128.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 129.ABBOTT LABORATORIES: NET SALES,
  • TABLE 130.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 131.DEXCOM, INC: COMPANY SNAPSHOT
  • TABLE 132.DEXCOM, INC: OPERATING SEGMENTS
  • TABLE 133.DEXCOM, INC: PRODUCT PORTFOLIO
  • TABLE 134.DEXCOM, INC: NET SALES,
  • TABLE 135.DEXCOM, INC: KEY STRATERGIES
  • TABLE 136.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 137.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 138.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 139.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 140.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 141.GLYSENS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 142.GLYSENS INCORPORATED: OPERATING SEGMENTS
  • TABLE 143.GLYSENS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 144.GLYSENS INCORPORATED: NET SALES,
  • TABLE 145.GLYSENS INCORPORATED: KEY STRATERGIES
  • TABLE 146.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 147.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 148.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 149.JOHNSON & JOHNSON: NET SALES,
  • TABLE 150.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 151.MANNKIND CORPORATION: COMPANY SNAPSHOT
  • TABLE 152.MANNKIND CORPORATION: OPERATING SEGMENTS
  • TABLE 153.MANNKIND CORPORATION: PRODUCT PORTFOLIO
  • TABLE 154.MANNKIND CORPORATION: NET SALES,
  • TABLE 155.MANNKIND CORPORATION: KEY STRATERGIES
  • TABLE 156.MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 157.MEDTRONIC PLC: OPERATING SEGMENTS
  • TABLE 158.MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 159.MEDTRONIC PLC: NET SALES,
  • TABLE 160.MEDTRONIC PLC: KEY STRATERGIES
  • TABLE 161.NOVO NORDISK A/S: COMPANY SNAPSHOT
  • TABLE 162.NOVO NORDISK A/S: OPERATING SEGMENTS
  • TABLE 163.NOVO NORDISK A/S: PRODUCT PORTFOLIO
  • TABLE 164.NOVO NORDISK A/S: NET SALES,
  • TABLE 165.NOVO NORDISK A/S: KEY STRATERGIES
  • TABLE 166.SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 167.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 168.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 169.SANOFI S.A.: NET SALES,
  • TABLE 170.SANOFI S.A.: KEY STRATERGIES
  • TABLE 171.SENSEONICS HOLDINGS, INC.: COMPANY SNAPSHOT
  • TABLE 172.SENSEONICS HOLDINGS, INC.: OPERATING SEGMENTS
  • TABLE 173.SENSEONICS HOLDINGS, INC.: PRODUCT PORTFOLIO
  • TABLE 174.SENSEONICS HOLDINGS, INC.: NET SALES,
  • TABLE 175.SENSEONICS HOLDINGS, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 2.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030
  • FIGURE 3.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY PRODUCT,2020(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INHALABLE INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INSULIN PATCHES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CGM SYSTEMS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ARTIFICIAL PANCREAS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 18.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY DEMOGRAPHIC,2020(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ADULT POPULATION (>14YEARS) NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CHILD POPULATION (14YEARS) NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 21.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY INDICATION,2020(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF TYPE 1 DIABETES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF TYPE 2 DIABETES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 24.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY END USER,2020(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC/CLINICS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF ICUS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF HOME HEALTHCARE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
  • FIGURE 28.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY REGION,2020
  • FIGURE 29.U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 30.CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 31.MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 32.GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 33.FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 34.U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 35.ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 36.SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 37.REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 38.CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 39.JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 40.INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 41.AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 42.SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 43.REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 44.BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 45.SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 46.SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 47.REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
  • FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 52.COMPETITIVE DASHBOARD
  • FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 54.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 55.DEXCOM, INC.: NET SALES ,($MILLION)
  • FIGURE 56.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 57.GLYSENS INCORPORATED.: NET SALES ,($MILLION)
  • FIGURE 58.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 59.MANNKIND CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 60.MEDTRONIC PLC.: NET SALES ,($MILLION)
  • FIGURE 61.NOVO NORDISK A/S.: NET SALES ,($MILLION)
  • FIGURE 62.SANOFI S.A..: NET SALES ,($MILLION)
  • FIGURE 63.SENSEONICS HOLDINGS, INC..: NET SALES ,($MILLION)